Xeris Biopharma Holdings Inc (XERS)
R&D Expense Growth
21.47%
Quarterly · Period ending:
XERS R&D Expense Growth
Latest reported21.47%period ending
Latest reported21.47%period ending
XERS Quarterly R&D Growth (QoQ) (0.00% → 21.47%)
Latest values, visible window
High-resolution chart · PNG
XERS r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 21.4733% | |
| 11.5443% | |
| 5.2252% | |
| -7.1012% | |
| 3.8953% | |
| 27.2653% | |
| 3.4647% | |
| 2.24% | |
| -26.3649% | |
| 22.5478% | |
| 26.7779% | |
| -17.2992% | |
| 25.8165% | |
| -2.3613% | |
| -18.0043% | |
| 62.5336% | |
| -40.512% | |
| -38.0083% | |
| 78.0328% | |
| 5.2016% | |
| 33.5069% | |
| -21.0959% | |
| 31.8369% | |
| -26.7158% | |
| -20.4183% | |
| -46.4895% | |
| -19.9639% | |
| -19.7331% | |
| 46.8292% | |
| 6.2712% | |
| 13.931% | |
| 25.3313% | |
| -0.4017% | |
| 32.4415% | |
| 14.8996% | |
| 36.2771% | |
| 14.7187% | |
| 0% |